Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Don't Treat Ghosts: Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA

ID
Name
025.PHA.2023.A
Description
Osteomyelitis is described as infection and inflammation of the long bone or bone marrow, often due to an open wound, operation, or invasive trauma.1 It is invasive and involves hematogenous seeding or contiguous spread of the infectious organism
Trial arms
Trial start
2023-06-23
Estimated PCD
2024-06-23
Trial end
2024-06-23
Status
Recruiting
Treatment
Anti-MRSA therapy
chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.
Other names:
Anti-MRSA Antibiotics
Size
365
Primary endpoint
Comparison of treatment
180 Days
Eligibility criteria
Inclusion Criteria: * • Admission to any MHS hospital between April 1, 2017 and April 1, 2023 * \> 18 years of age * Documented osteomyelitis location of the lower limb via ICD-10 code * Documented imaging of lower limb osteomyelitis during index admission * Planned intravenous (IV) antibiotics for at least 4 weeks Exclusion Criteria: * • IV antibiotics for less than 24 hours inpatient * Planned surgical intervention documented at admission * Patients receiving monotherapy with an anti-MRSA agent * Positive MRSA culture during index admission * Current outpatient antibiotic use on index admission * Repeated hospital admission during study period
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 365, 'type': 'ESTIMATED'}}
Updated at
2023-10-23

1 organization

1 product

1 indication

Organization
Methodist Health System
Product
Anti-MRSA therapy
Indication
Osteomyelitis